Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
Thoracic Cancer|February 21, 2020
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failureTakaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, et al.
Translational Lung Cancer Research|August 14, 2023
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective studyTomoaki Nakamura, Tatsuya Yoshida, Yuki Takeyasu, et al.
Respiratory Investigation|December 2, 2022
Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodiesTomohiro Tanaka, Tatsuya Yoshida, Ken Masuda, et al.
Clinical Lung Cancer|November 22, 2021
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)Yoshimasa Shiraishi, Taiki Hakozaki, Shogo Nomura, et al.
Journal of Thoracic Disease|June 11, 2019
Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective studyKazushi Yoshida, Shintaro Kanda, Hideaki Shiraishi, et al.
Anticancer Research|December 3, 2024
Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical PracticeAkiko Tateishi, Yusuke Okuma, Yasushi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|October 11, 2020
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Yuji Matsumoto, et al.
Japanese Journal of Clinical Oncology|September 6, 2013
Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective studyHidehito Horinouchi, Kaoru Kubota, Hidetoshi Itani, et al.
The Lancet Regional Health. Western Pacific|October 9, 2024
Drug development and evidence for lung cancer targeted therapy in Eastern AsiaSi-Yang Maggie Liu, Zhen-Yi Jin, Jia-Yi Deng, et al.
Clinical Lung Cancer|November 22, 2016
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung CancerHitomi Sumiyoshi Okuma, Hidehito Horinouchi, Shinsuke Kitahara, et al.
Pageof 22